Analyst Ratings For Quest Diagnostics Inc (NYSE:DGX)
Today, Quest Diagnostics Inc (NYSE:DGX) stock received an upgrade by Jefferies Financial Group from Hold to Buy.
There are 9 Hold Ratings, 9 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Quest Diagnostics Inc (NYSE:DGX) is Hold with a consensus target price of $101.4375 per share, a potential 12.53% upside.
Some recent analyst ratings include
- 4/2/2019-Quest Diagnostics Inc (NYSE:DGX) gets upgraded to Buy by Jefferies Financial Group
- 3/18/2019-Quest Diagnostics Inc (NYSE:DGX) gets downgraded to Neutral by Credit Suisse Group with a price target of $91.00
- 2/18/2019-Quest Diagnostics Inc (NYSE:DGX) had its Buy rating reiterated by Canaccord Genuity with a $97.00 price target
- 2/15/2019-Quest Diagnostics Inc (NYSE:DGX) had its Buy rating reiterated by Barclays with a $114.00 price target
- On 3/4/2019 Everett Cunningham, SVP, sold 3,892 with an average share price of $86.81 per share and the total transaction amounting to $337,864.52.
- On 2/27/2019 Everett Cunningham, SVP, sold 1,496 with an average share price of $86.64 per share and the total transaction amounting to $129,613.44.
- On 2/25/2019 Michael E Prevoznik, SVP, sold 336 with an average share price of $88.23 per share and the total transaction amounting to $29,645.28.
- On 2/22/2019 Gail R Wilensky, Director, sold 8,000 with an average share price of $87.78 per share and the total transaction amounting to $702,240.00.
- On 7/10/2018 Everett Cunningham, SVP, sold 40,328 with an average share price of $112.00 per share and the total transaction amounting to $4,516,736.00.
- On 7/2/2018 Everett Cunningham, SVP, sold 68,069 with an average share price of $109.67 per share and the total transaction amounting to $7,465,127.23.
- On 5/29/2018 Jeffrey M Leiden, Director, sold 1,644 with an average share price of $105.61 per share and the total transaction amounting to $173,622.84.
About Quest Diagnostics Inc (NYSE:DGX)
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Recent Trading Activity for Quest Diagnostics Inc (NYSE:DGX)
Shares of Quest Diagnostics Inc closed the previous trading session at 90.14 up +0.22 0.24% with 89.83 shares trading hands.